Last reviewed · How we verify
Colloid
At a glance
| Generic name | Colloid |
|---|---|
| Also known as | HES 130/0.4, Voluven, Venofundin, Tetraspan |
| Sponsor | University of Nottingham |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults (PHASE1, PHASE2)
- Gelaspan vs Crystalloid Therapy in Sepsis (PHASE4)
- Pain Experience Using Lidocaine Adrenaline Tetracaine (LAT) Gel Versus Lidocaine Infiltration for Laceration Repair in Adults (PHASE4)
- Topical 5% Spironolactone Gel Versus 0.1% Adapalene Gel for Acne Vulgaris: A Randomized Split-Face Study (PHASE2)
- Comparing Chitosan Sponge With Hydrocolloid as Dressing for Split-thickness Skin Graft Donor Site Wounds (NA)
- A Study（Phase I）of GS3-007a Dry Suspension in Healthy Chinese Adults (PHASE1)
- A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE) (PHASE3)
- Initial Resuscitation for Acute Kidney Injury in Cirrhosis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Colloid CI brief — competitive landscape report
- Colloid updates RSS · CI watch RSS
- University of Nottingham portfolio CI